Sepsis Clinical Trial
— PSSS_digitalOfficial title:
Personalized Swiss Sepsis Study: With Machine Learning and Computational Modelling Towards Personalized Sepsis Management - Discovery of Digital Biomarkers
This multi-center study is to focus on patients with sepsis in Intensive Care Units (ICUs) in order to better understand the complex host-pathogen interaction and clinical heterogeneity associated with sepsis. Understanding this heterogeneity may allow the development of novel diagnostic approaches. Data from patients will be analyzed using state-of-the art analytical algorithms for biomarker discovery including machine learning and multidimensional mathematical modelling to explore the large datasets generated. In order to discover digital biomarkers for the study endpoints a case-control study design will be used to compare data patterns from patients with sepsis (cases) and those without sepsis (controls).
Status | Recruiting |
Enrollment | 17500 |
Est. completion date | June 2023 |
Est. primary completion date | June 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients admitted to an ICU on a Swiss University Hospital. - Patients expected to stay at least 24h on the ICU Inclusion Criteria (cases) - Present at admission to ICU or subsequent development of sepsis 3.0 criteria Inclusion Criteria (controls) - Patients not fulfilling sepsis definition during the ICU stay Exclusion Criteria: - Decline of general consent or any other negative statement against using data for research. - Patients with a clear elective stay on the ICUs. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Clinical Microbiology, University Hospital Basel | Basel | |
Switzerland | Infectious Diseases and Hospital Epidemiology, University Hospital Basel | Basel | |
Switzerland | Medical Intensive Care Unit; University Hospital Basel | Basel | |
Switzerland | Surgical Intensive Care Unit, University Hospital Basel | Basel | |
Switzerland | Division Infectious Diseases, University Hospital Bern | Bern | |
Switzerland | Institute for Infectious Diseases, University of Bern | Bern | |
Switzerland | Intensive Care Medicine, University Hospital Bern | Bern | |
Switzerland | Division Bacteriology Laboratory, University Hospital Geneva | Geneva | |
Switzerland | Division Infectious Diseases, University Hospital Geneva | Geneva | |
Switzerland | Intensive Care Medicine, University Hospital Geneva | Geneva | |
Switzerland | Division Intensive Care Medicine, University Hospital Lausanne | Lausanne | |
Switzerland | Institute of Microbiology, University Hospital Lausanne | Lausanne | |
Switzerland | Service Infectious Diseases, University Hospital Lausanne | Lausanne | |
Switzerland | Division Infectious Diseases, University Hospital Zurich | Zürich | |
Switzerland | Institute for Intensive Medicine, University Hospital Zurich | Zürich | |
Switzerland | Institute for Medical Microbiology, University Hospital Zurich | Zürich |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland | Personalized Health and Related Technologies (PHRT) initiative of ETH Zürich, Swiss Personalized Health Network (SPHN) |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | sepsis-related mortality (sensitivity) | Algorithm to predict sepsis-related mortality (sensitivity) | time- series data collected from hospital entry until maximum 12 months after hospital exit (no exact time point specified) | |
Primary | sepsis-related mortality (specificity) | Algorithm to predict sepsis-related mortality (specificity) | time- series data collected from hospital entry until maximum 12 months after hospital exit (no exact time point specified) | |
Primary | Determination of sepsis | Algorithm to determine sepsis at an early stage (at least 12 hours before classical definitions) | time- series data collected from hospital entry until hospital exit; an average of 1 month (no exact time point specified) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |